Published in PLoS Pathog on January 19, 2012
Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun (2012) 1.05
IL-12Rβ2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol (2013) 0.91
Identification of a live attenuated vaccine candidate for tularemia prophylaxis. PLoS One (2013) 0.85
T-bet regulates immunity to Francisella tularensis live vaccine strain infection, particularly in lungs. Infect Immun (2014) 0.83
A Francisella tularensis live vaccine strain that improves stimulation of antigen-presenting cells does not enhance vaccine efficacy. PLoS One (2012) 0.82
Francisella tularensis Vaccines Elicit Concurrent Protective T- and B-Cell Immune Responses in BALB/cByJ Mice. PLoS One (2015) 0.80
Correlates of Vaccine-Induced Protection against Mycobacterium tuberculosis Revealed in Comparative Analyses of Lymphocyte Populations. Clin Vaccine Immunol (2015) 0.78
Preclinical testing of a vaccine candidate against tularemia. PLoS One (2015) 0.77
Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain. Clin Vaccine Immunol (2013) 0.77
Some extensions in continuous models for immunological correlates of protection. BMC Med Res Methodol (2015) 0.77
Activities of Murine Peripheral Blood Lymphocytes Provide Immune Correlates That Predict Francisella tularensis Vaccine Efficacy. Infect Immun (2016) 0.76
Rapid countermeasure discovery against Francisella tularensis based on a metabolic network reconstruction. PLoS One (2013) 0.76
An In Vitro Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of Francisella tularensis SCHU S4 and Identifies Nitric Oxide as a Predictor of Efficacy. Front Cell Infect Microbiol (2016) 0.75
Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity. Clin Vaccine Immunol (2017) 0.75
Tularemia as a biological weapon: medical and public health management. JAMA (2001) 13.23
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol (2008) 11.65
Vaccine Prophylaxis against Tularemia in Man. Am J Public Health Nations Health (1942) 10.47
Prophylactic effectiveness of live and killed tularemia vaccines. I. Production of vaccine and evaluation in the white mouse and guinea pig. J Immunol (1961) 7.52
T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat Immunol (2002) 7.28
Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol (2005) 5.27
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med (1961) 5.12
Nature of protective immunity to Francisella tularensis. Rev Infect Dis (1989) 4.75
IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev (2008) 4.68
Live vaccine strain of Francisella tularensis: infection and immunity in mice. Infect Immun (1991) 3.99
A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis (2007) 3.95
Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med (1961) 3.90
Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis (1977) 3.51
Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev (2004) 3.18
Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol (2008) 3.04
Dominant TNF-α+ Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. Nat Med (2011) 2.77
Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol (2009) 2.72
Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med (2010) 2.64
Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A (2007) 2.62
Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect (2003) 2.48
Innate and adaptive immunity to Francisella. Ann N Y Acad Sci (2007) 2.32
Intracellular survival mechanisms of Francisella tularensis, a stealth pathogen. Microbes Infect (2005) 2.23
In vivo clearance of an intracellular bacterium, Francisella tularensis LVS, is dependent on the p40 subunit of interleukin-12 (IL-12) but not on IL-12 p70. Infect Immun (2002) 2.02
Susceptibility to secondary Francisella tularensis live vaccine strain infection in B-cell-deficient mice is associated with neutrophilia but not with defects in specific T-cell-mediated immunity. Infect Immun (2001) 1.91
Immunodominant Francisella tularensis antigens identified using proteome microarray. Proteomics (2007) 1.85
Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol Microbiol (1996) 1.69
Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing. Clin Vaccine Immunol (2010) 1.64
Animal models of Francisella tularensis infection. Ann N Y Acad Sci (2007) 1.55
Nucleotide sequence and T cell epitopes of a membrane protein of Francisella tularensis. J Immunol (1990) 1.50
Correlates of protective immunity to Mycobacterium tuberculosis in humans. Clin Infect Dis (2000) 1.46
Vaccines against Francisella tularensis. Ann N Y Acad Sci (2007) 1.46
Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med (2003) 1.45
CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med (2005) 1.44
Half-truths and selective memory: Interferon gamma, CD4(+) T cells and protective memory against tuberculosis. Tuberculosis (Edinb) (2007) 1.44
The tularaemia vaccine. J Chem Technol Biotechnol (1994) 1.43
Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine (1995) 1.40
Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine (2011) 1.39
Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol (2008) 1.36
Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun (2008) 1.31
Tuberculosis in Africa: learning from pathogenesis for biomarker identification. Cell Host Microbe (2008) 1.30
Polyfunctional T cells in human tuberculosis. Eur J Immunol (2010) 1.25
A comparison of IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb) (2008) 1.21
Establishing efficacy of human products using animals: the US food and drug administration's "animal rule". Vet Pathol (2010) 1.19
Francisella tularensis--a model for studies of the immune response to intracellular bacteria in man. Immunology (1992) 1.18
PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg (2005) 1.14
Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy. PLoS One (2010) 1.13
Development of a murine mycobacterial growth inhibition assay for evaluating vaccines against Mycobacterium tuberculosis. Clin Vaccine Immunol (2009) 1.13
Mapping of immunoreactive antigens of Francisella tularensis live vaccine strain. Proteomics (2002) 1.11
Francisella tularensis vaccines. Vaccine (2009) 1.11
Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol (2011) 1.11
The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol (2010) 1.10
Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS). Microb Pathog (2007) 1.05
Identification of immunoreactive antigens in membrane proteins enriched fraction from Francisella tularensis LVS. Immunol Lett (2007) 1.02
Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J Immunol (2009) 0.97
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans. Vaccine (2009) 0.97
Infection of mice with Francisella as an immunological model. Curr Protoc Immunol (2011) 0.96
A key role for lung-resident memory lymphocytes in protective immune responses after BCG vaccination. Eur J Immunol (2010) 0.95
T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect Immun (2009) 0.94
Francisella tularensis-induced in vitro gamma interferon, tumor necrosis factor alpha, and interleukin 2 responses appear within 2 weeks of tularemia vaccination in human beings. J Clin Microbiol (1991) 0.94
Measurement of macrophage-mediated killing of intracellular bacteria, including Francisella and mycobacteria. Curr Protoc Immunol (2011) 0.93
Transcriptional profiling of Francisella tularensis infected peripheral blood mononuclear cells: a predictive tool for tularemia. FEMS Immunol Med Microbiol (2008) 0.89
Identification of T-cell epitopes in Francisella tularensis using an ordered protein array of serological targets. Immunology (2011) 0.88
Identification of a dominant CD4 T cell epitope in the membrane lipoprotein Tul4 from Francisella tularensis LVS. Mol Immunol (2009) 0.87
A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine (2009) 0.87
Immunogenicity of a new lot of Francisella tularensis live vaccine strain in human volunteers. FEMS Immunol Med Microbiol (1996) 0.85
Expression of interferon-gamma and tumour necrosis factor-alpha messenger RNA does not correlate with protection in guinea pigs challenged with virulent Mycobacterium tuberculosis by the respiratory route. Immunology (2008) 0.85
Generation of heterogeneous memory T cells by live attenuated tularemia vaccine in humans. Vaccine (2009) 0.78
A Francisella tularensis pathogenicity island required for intramacrophage growth. J Bacteriol (2004) 4.67
A Tn7-based broad-range bacterial cloning and expression system. Nat Methods (2005) 4.66
Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med (2002) 3.88
Sickle cell trait is associated with a delayed onset of malaria: implications for time-to-event analysis in clinical studies of malaria. J Infect Dis (2008) 2.77
Innate and adaptive immune responses to an intracellular bacterium, Francisella tularensis live vaccine strain. Microbes Infect (2003) 2.48
Innate and adaptive immunity to Francisella. Ann N Y Acad Sci (2007) 2.32
Francisella novicida LPS has greater immunobiological activity in mice than F. tularensis LPS, and contributes to F. novicida murine pathogenesis. Microbes Infect (2003) 2.31
Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med (2008) 2.24
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med (2012) 2.17
Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol (2006) 2.16
Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis (2011) 2.12
Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol (2009) 2.10
Parasite burden and severity of malaria in Tanzanian children. N Engl J Med (2014) 2.07
The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog (2010) 2.03
Intracellular biology and virulence determinants of Francisella tularensis revealed by transcriptional profiling inside macrophages. Cell Microbiol (2009) 2.00
Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages. Infect Immun (2007) 1.98
An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis (2013) 1.72
The Francisella pathogenicity island protein PdpD is required for full virulence and associates with homologues of the type VI secretion system. J Bacteriol (2008) 1.71
Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol (2008) 1.64
Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A (2009) 1.61
Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun (2008) 1.56
Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis (2010) 1.53
Neutralizing antibody titers conferring protection to macaques from a simian/human immunodeficiency virus challenge using the TZM-bl assay. AIDS Res Hum Retroviruses (2010) 1.50
The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol (2009) 1.50
Accounting for variability in sample size estimation with applications to nonadherence and estimation of variance and effect size. Biometrics (2007) 1.49
CD4+ T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol (2003) 1.49
Multiple T cell subsets control Francisella tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp Med (2003) 1.45
Myeloid differentiation factor-88 (MyD88) is essential for control of primary in vivo Francisella tularensis LVS infection, but not for control of intra-macrophage bacterial replication. Microbes Infect (2006) 1.45
Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med (2004) 1.44
CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med (2005) 1.44
In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect Immun (2009) 1.39
Immunity to Francisella. Front Microbiol (2011) 1.37
Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol (2010) 1.34
Naturally acquired antibodies specific for Plasmodium falciparum reticulocyte-binding protein homologue 5 inhibit parasite growth and predict protection from malaria. J Infect Dis (2013) 1.30
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol (2007) 1.29
Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. J Immunol (2009) 1.24
Disciplinary action against physicians: who is likely to get disciplined? Am J Med (2005) 1.24
Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) (2007) 1.20
Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antimicrob Agents Chemother (2009) 1.14
A latent autoregressive model for longitudinal binary data subject to informative missingness. Biometrics (2002) 1.13
The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine (2009) 1.13
Virulence variation among isolates of western equine encephalitis virus in an outbred mouse model. J Gen Virol (2009) 1.11
Objections to the transfer of Francisella novicida to the subspecies rank of Francisella tularensis. Int J Syst Evol Microbiol (2010) 1.06
Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood (2004) 1.06
Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun (2012) 1.05
IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis. J Immunol (2011) 1.05
Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One (2012) 1.04
Diverse myeloid and lymphoid cell subpopulations produce gamma interferon during early innate immune responses to Francisella tularensis live vaccine strain. Infect Immun (2008) 1.04
A novel role for plasmin-mediated degradation of opsonizing antibody in the evasion of host immunity by virulent, but not attenuated, Francisella tularensis. J Immunol (2009) 1.03
The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo. Infect Immun (2009) 1.03
Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals. AIDS (2011) 1.02
Engaging communities in tuberculosis research. Lancet Infect Dis (2013) 1.01
Differential effects of HIV viral load and CD4 count on proliferation of naive and memory CD4 and CD8 T lymphocytes. Blood (2011) 1.00
Interferon-alpha produces significant decreases in HIV load. J Interferon Cytokine Res (2010) 0.99
CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis (2008) 0.99
Characterization of the pathogenicity island protein PdpA and its role in the virulence of Francisella novicida. Microbiology (2009) 0.99
Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays. Clin Vaccine Immunol (2009) 0.99
Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth. J Immunol (2007) 0.98
Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor α. Clin Vaccine Immunol (2013) 0.97
Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens. PLoS Pathog (2010) 0.97
A maximum pseudo-profile likelihood estimator for the Cox model under length-biased sampling. Biometrika (2012) 0.97
Infection of mice with Francisella as an immunological model. Curr Protoc Immunol (2011) 0.96
The membrane form of tumor necrosis factor is sufficient to mediate partial innate immunity to Francisella tularensis live vaccine strain. J Infect Dis (2008) 0.95
Molecular mechanisms of filovirus cellular trafficking. Microbes Infect (2003) 0.95
Survival of secondary lethal systemic Francisella LVS challenge depends largely on interferon gamma. Microbes Infect (2009) 0.95
T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect Immun (2009) 0.94
Semiparametric dimension reduction estimation for mean response with missing data. Biometrika (2010) 0.94
Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs. Vaccine (2010) 0.94
Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination. PLoS One (2012) 0.93
A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun (2008) 0.92
NKp30-dependent cytolysis of filovirus-infected human dendritic cells. Cell Microbiol (2007) 0.92
Epicutaneous model of community-acquired Staphylococcus aureus skin infections. Infect Immun (2013) 0.92
IL-12Rβ2 is critical for survival of primary Francisella tularensis LVS infection. J Leukoc Biol (2013) 0.91
B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses. J Immunol (2013) 0.91
Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA vaccine alone. J Infect Dis (2002) 0.90
A valid formulation of the analysis of noninferiority trials under random effects meta-analysis. Biostatistics (2012) 0.90
Essential genes from Arctic bacteria used to construct stable, temperature-sensitive bacterial vaccines. Proc Natl Acad Sci U S A (2010) 0.89
Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol (2013) 0.89
Random effects and latent processes approaches for analyzing binary longitudinal data with missingness: a comparison of approaches using opiate clinical trial data. Stat Methods Med Res (2007) 0.89
Analysis of recurrent gap time data using the weighted risk-set method and the modified within-cluster resampling method. Stat Med (2011) 0.86
Comparison of resource utilization and clinical outcomes between teaching and nonteaching medical services. J Hosp Med (2007) 0.86
Parametric and semiparametric approaches to testing for seasonal trend in serial count data. Biostatistics (2002) 0.85
The accelerated biased coin up-and-down design in phase I trials. J Biopharm Stat (2004) 0.85
A model checking method for the proportional hazards model with recurrent gap time data. Biostatistics (2010) 0.84
T-bet regulates immunity to Francisella tularensis live vaccine strain infection, particularly in lungs. Infect Immun (2014) 0.83
Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr (2011) 0.83
Alternative activation of macrophages and induction of arginase are not components of pathogenesis mediated by Francisella species. PLoS One (2013) 0.82
Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood (2004) 0.82
Genetic polymorphisms of eosinophil-derived neurotoxin and eosinophil cationic protein in tropical pulmonary eosinophilia. Am J Trop Med Hyg (2005) 0.82
Kernel Estimation of Rate Function for Recurrent Event Data. Scand Stat Theory Appl (2005) 0.81